{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:20:24Z","timestamp":1786980024108,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) of South Korea","award":["2020R1F1A1072209"],"award-info":[{"award-number":["2020R1F1A1072209"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-022-04195-w","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:02:56Z","timestamp":1667217776000},"page":"3043-3048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean population-based cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-8581","authenticated-orcid":false,"given":"Jae-Hyun","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-1232","authenticated-orcid":false,"given":"Jae Sang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9177-2553","authenticated-orcid":false,"given":"Yunhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-1034","authenticated-orcid":false,"given":"Jun-Pyo","family":"Myong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-0588","authenticated-orcid":false,"given":"U-Syn","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"4195_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S071498081000070X","volume":"30","author":"NM Peel","year":"2011","unstructured":"Peel NM (2011) Epidemiology of falls in older age. Can J Aging 30:7\u201319. https:\/\/doi.org\/10.1017\/S071498081000070X","journal-title":"Can J Aging"},{"key":"4195_CR2","unstructured":"World Health Organization (2021) Falls. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/falls Accessed March 15 2022"},{"key":"4195_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1060028019880305","volume":"54","author":"CC McDonnell","year":"2020","unstructured":"McDonnell CC, Rogers KC, Regen SM, Finks SW (2020) The fall risk with alpha blockers given initial dose or elderly status (FRAGILE) study. Ann Pharmacother 54:226\u2013231. https:\/\/doi.org\/10.1177\/1060028019880305","journal-title":"Ann Pharmacother"},{"key":"4195_CR4","first-page":"703","volume":"45","author":"C Forray","year":"1994","unstructured":"Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA (1994) The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol 45:703\u2013708","journal-title":"Mol Pharmacol"},{"key":"4195_CR5","first-page":"S9","volume":"11","author":"H Lepor","year":"2009","unstructured":"Lepor H (2009) Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol 11:S9\u2013S13","journal-title":"Rev Urol"},{"key":"4195_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0022-5347(05)67426-5","volume":"164","author":"S Murata","year":"2000","unstructured":"Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I (2000) Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 164:578\u2013583","journal-title":"J Urol"},{"issue":"Suppl 4","key":"4195_CR7","first-page":"S3","volume":"8","author":"H Lepor","year":"2006","unstructured":"Lepor H (2006) The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 8(Suppl 4):S3-9","journal-title":"Rev Urol"},{"key":"4195_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-410x.1987.tb04950.x","volume":"60","author":"RS Kirby","year":"1987","unstructured":"Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan M, Milroy EJ (1987) Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 60:136\u2013142. https:\/\/doi.org\/10.1111\/j.1464-410x.1987.tb04950.x","journal-title":"Br J Urol"},{"key":"4195_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ucl.2016.04.009","volume":"43","author":"H Lepor","year":"2016","unstructured":"Lepor H (2016) Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin N Am 43:311\u2013323. https:\/\/doi.org\/10.1016\/j.ucl.2016.04.009","journal-title":"Urol Clin N Am"},{"key":"4195_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","volume":"15","author":"DA Schwinn","year":"2008","unstructured":"Schwinn DA, Roehrborn CG (2008) Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15:193\u2013199. https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01956.x","journal-title":"Int J Urol"},{"key":"4195_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6320","volume":"347","author":"ST Bird","year":"2013","unstructured":"Bird ST, Delaney JAC, Brophy JM, Etminan M, Skeldon SC, Hartzema AG (2013) Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40\u201385 years in the United States: risk window analyses using between and within patient methodology. BMJ 347:f6320. https:\/\/doi.org\/10.1136\/bmj.f6320","journal-title":"BMJ"},{"key":"4195_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1046\/j.1464-410x.2000.00546.x","volume":"85","author":"RD Mann","year":"2000","unstructured":"Mann RD, Biswas P, Freemantle S, Pearce G, Wilton L (2000) The pharmacovigilance of tamsulosin: event data on 12484 patients. BJU Int 85:446\u2013450. https:\/\/doi.org\/10.1046\/j.1464-410x.2000.00546.x","journal-title":"BJU Int"},{"key":"4195_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5398","volume":"351","author":"B Welk","year":"2015","unstructured":"Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, Hwang YJ, Ordon M (2015) The risk of fall and fracture with the initiation of a prostate-selective \u03b1 antagonist: a population based cohort study. BMJ 351:h5398. https:\/\/doi.org\/10.1136\/bmj.h5398","journal-title":"BMJ"},{"key":"4195_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00002512-200219020-00004","volume":"19","author":"CJ Dunn","year":"2002","unstructured":"Dunn CJ, Matheson A, Faulds DM (2002) Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 19:135\u2013161. https:\/\/doi.org\/10.2165\/00002512-200219020-00004","journal-title":"Drugs Aging"},{"key":"4195_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14656566.7.5.583","volume":"7","author":"MM Elhilali","year":"2006","unstructured":"Elhilali MM (2006) Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother 7:583\u2013596. https:\/\/doi.org\/10.1517\/14656566.7.5.583","journal-title":"Expert Opin Pharmacother"},{"key":"4195_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.urology.2013.07.062","volume":"82","author":"CP Filson","year":"2013","unstructured":"Filson CP, Wei JT, Hollingsworth JM (2013) Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 82:1386\u20131392. https:\/\/doi.org\/10.1016\/j.urology.2013.07.062","journal-title":"Urology"},{"key":"4195_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1248\/yakushi.126.209","volume":"126","author":"S Tatemichi","year":"2006","unstructured":"Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N (2006) Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126:209\u2013216. https:\/\/doi.org\/10.1248\/yakushi.126.209","journal-title":"Yakugaku Zasshi"},{"key":"4195_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1254\/fpj.116.63","volume":"116","author":"I Ikegaki","year":"2000","unstructured":"Ikegaki I (2000) Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia. Nihon Yakurigaku Zasshi 116:63\u201369. https:\/\/doi.org\/10.1254\/fpj.116.63","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"4195_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234787","volume":"15","author":"T Kim","year":"2020","unstructured":"Kim T, Choi SD, Xiong S (2020) Epidemiology of fall and its socioeconomic risk factors in community-dwelling Korean elderly. PLoS ONE 15:e0234787. https:\/\/doi.org\/10.1371\/journal.pone.0234787","journal-title":"PLoS ONE"},{"key":"4195_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/BF03324636","volume":"18","author":"A Weiss","year":"2006","unstructured":"Weiss A, Beloosesky Y, Grinblat J, Grossman E (2006) Seasonal changes in orthostatic hypotension among elderly admitted patients. Aging Clin Exp Res 18:20\u201324. https:\/\/doi.org\/10.1007\/BF03324636","journal-title":"Aging Clin Exp Res"},{"key":"4195_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/hr.2015.96","volume":"38","author":"GS Stergiou","year":"2015","unstructured":"Stergiou GS, Myrsilidi A, Kollias A, Destounis A, Roussias L, Kalogeropoulos P (2015) Seasonal variation in meteorological parameters and office, ambulatory and home blood pressure: predicting factors and clinical implications. Hypertens Res 38:869\u2013875. https:\/\/doi.org\/10.1038\/hr.2015.96","journal-title":"Hypertens Res"},{"key":"4195_CR22","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.jamda.2021.07.010","volume":"22","author":"U Hohtari-Kivim\u00e4ki","year":"2021","unstructured":"Hohtari-Kivim\u00e4ki U, Salminen M, Vahlberg T, Kivel\u00e4 SL (2021) Orthostatic hypotension is a risk factor for falls among older adults: 3-year follow-up. J Am Med Dir Assoc 22:2325\u20132330. https:\/\/doi.org\/10.1016\/j.jamda.2021.07.010","journal-title":"J Am Med Dir Assoc"},{"key":"4195_CR23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0091270004268128","volume":"44","author":"K Kim","year":"2004","unstructured":"Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083\u20131105. https:\/\/doi.org\/10.1177\/0091270004268128","journal-title":"J Clin Pharmacol"},{"key":"4195_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J (2021) Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect 9:e00890. https:\/\/doi.org\/10.1002\/prp2.890","journal-title":"Pharmacol Res Perspect"},{"key":"4195_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/a:1010639201787","volume":"19","author":"M Sawyer","year":"2001","unstructured":"Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171\u2013177. https:\/\/doi.org\/10.1023\/a:1010639201787","journal-title":"Invest New Drugs"},{"key":"4195_CR26","doi-asserted-by":"publisher","DOI":"10.5402\/2013\/370340","volume":"2013","author":"SE Mitchell","year":"2013","unstructured":"Mitchell SE, Aitken SA, Court-Brown CM (2013) The epidemiology of fractures caused by falls down stairs. ISRN Epidemiology 2013:370340. https:\/\/doi.org\/10.5402\/2013\/370340","journal-title":"ISRN Epidemiology"},{"key":"4195_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1476-5381.1993.tb13762.x","volume":"109","author":"F Lef\u00e8vre-Borg","year":"1993","unstructured":"Lef\u00e8vre-Borg F, O\u2019Connor SE, Schoemaker H, Hicks PE, Lechaire J, Gautier E, Pierre F, Pimoule C, Manoury P, Langer SZ (1993) Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109:1282\u20131289. https:\/\/doi.org\/10.1111\/j.1476-5381.1993.tb13762.x","journal-title":"Br J Pharmacol"},{"key":"4195_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"JA Kim","year":"2017","unstructured":"Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718\u2013728. https:\/\/doi.org\/10.3346\/jkms.2017.32.5.718","journal-title":"J Korean Med Sci"},{"issue":"Suppl 2","key":"4195_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ageing\/afl084","volume":"35","author":"LZ Rubenstein","year":"2006","unstructured":"Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing 35(Suppl 2):37\u201341. https:\/\/doi.org\/10.1093\/ageing\/afl084","journal-title":"Age Ageing"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04195-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T09:07:53Z","timestamp":1669799273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04195-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04195-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Catholic University of Korea (KC21ZESI0096).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}